| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mercy Jelagat Karoney | Q47174980 |
| P2093 | author name string | Abraham Mosigisi Siika | |
| Mercy Jelagat Karoney | |||
| P2860 | cites work | Epidemiology of hepatitis C virus infection | Q22305500 |
| Laboratory Assays for Diagnosis and Management of Hepatitis C Virus Infection | Q27473492 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Hepatitis C virus in Arab world: a state of concern. | Q55425412 | ||
| National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C | Q73717356 | ||
| EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver | Q77872085 | ||
| Treatment of hepatitis C | Q81014953 | ||
| Hepatitis C virus infection | Q27861002 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention | Q28286743 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Natural history of chronic hepatitis C | Q29620673 | ||
| Unsafe injections in the developing world and transmission of bloodborne pathogens: a review | Q33791766 | ||
| Pathogenesis, natural history, treatment, and prevention of hepatitis C. | Q33841882 | ||
| The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt | Q33884428 | ||
| Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. | Q33982107 | ||
| Epidemiology of hepatitis C virus (HCV) infection | Q33995067 | ||
| Global challenges in liver disease | Q33999114 | ||
| Management of acute hepatitis C. | Q34096207 | ||
| Is sexual contact a major mode of hepatitis C virus transmission? | Q34126319 | ||
| Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis | Q34129214 | ||
| Caring for pregnant women and newborns with hepatitis B or C. | Q34152706 | ||
| Molecular diagnosis of viral hepatitis | Q34642858 | ||
| Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa | Q34683612 | ||
| Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis | Q34779247 | ||
| Global burden of disease (GBD) for hepatitis C. | Q35610002 | ||
| Current therapy for hepatitis C. | Q36263113 | ||
| Hepatitis C virus infection in African Americans | Q36328945 | ||
| Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? | Q36341028 | ||
| Epidemiology of hepatitis B and C viruses: a global overview | Q37685594 | ||
| The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach | Q39372016 | ||
| Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa | Q39467762 | ||
| Standardization of hepatitis C virus RNA quantification | Q42999984 | ||
| Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission | Q43000555 | ||
| Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. | Q43035368 | ||
| Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). | Q43039862 | ||
| Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection | Q43041409 | ||
| The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States | Q45297557 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings | Q46828957 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Africa | Q15 | ||
| Hepatitis C virus | Q708693 | ||
| RNA virus infectious disease | Q18967413 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 44 | |
| P577 | publication date | 2013-01-01 | |
| 2013-01-31 | |||
| P1433 | published in | The Pan African medical journal | Q27722840 |
| P1476 | title | Hepatitis C virus (HCV) infection in Africa: a review | |
| P478 | volume | 14 |
| Q36316465 | "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda |
| Q91630339 | Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources |
| Q36811958 | Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection |
| Q30382346 | Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia |
| Q36072412 | Clinical and imaging characteristics of orbital metastatic lesions among Egyptian patients |
| Q37628056 | Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, northwest Ethiopia |
| Q38932103 | Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. |
| Q37714088 | Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C |
| Q41084425 | Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans |
| Q26781996 | Epidemiology of hepatitis C virus in Iran |
| Q58740366 | Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study |
| Q35751678 | Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission |
| Q30245058 | Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes |
| Q91809814 | HCV Phylogeography of the General Population and High-Risk Groups in Cyprus Identifies the Island as a Global Sink for and Source of Infection |
| Q59350541 | Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study |
| Q36657463 | Hepatitis B virus and hepatitis C virus co-infection in hemodialysis patients: A retrospective study from a tertiary care hospital of North India |
| Q35661832 | Hepatitis B, Hepatitis C and HIV-1 Coinfection in Two Informal Urban Settlements in Nairobi, Kenya |
| Q39400280 | Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda |
| Q30398982 | Hepatitis C virus and HIV co-infection among pregnant women in Rwanda |
| Q39285786 | Hepatitis C virus genotypes in Kenya |
| Q37049123 | Hepatitis C virus genotypes in north eastern Algeria: A retrospective study |
| Q35738763 | Hepatitis C virus seroprevalence in the general female population from 8 countries |
| Q26862531 | Hepatitis C virus: A global view |
| Q36228804 | Hepatitis viruses in Ethiopia: a systematic review and meta-analysis |
| Q37312151 | Management of hepatitis C genotype 4 in the directly acting antivirals era. |
| Q36527644 | Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy |
| Q40741996 | NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection |
| Q38542377 | Occult hepatitis B virus infection in Egypt |
| Q40471249 | Occupational hazards of traditional healers: repeated unprotected blood exposures risk infectious disease transmission. |
| Q57296553 | Partnership with African Countries: European Society of Gastrointestinal Endoscopy (ESGE) - Position Statement |
| Q38719082 | Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania |
| Q33439743 | Prevalence of Hepatitis C Virus Infection and Its Risk Factors among Patients Attending Rwanda Military Hospital, Rwanda |
| Q56917918 | Prevalence of anti-hepatitis C antibodies and its co-infection with HIV in rural Cameroon |
| Q34982182 | Prevalence of hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya |
| Q35857431 | Prevalence of hepatitis B and C viruses infection among military personnel at Bahir Dar Armed Forces General Hospital, Ethiopia |
| Q95363154 | Prevalence of hepatitis C virus antibody among university students in Nigeria |
| Q35565353 | Prevalence of hepatitis C virus in mothers and their children in Malawi |
| Q91939966 | Prevalence of viral and non-viral hepatitis in Menoua Division, West Region, Cameroon: a retrospective hospital-based study |
| Q90196120 | Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study |
| Q26772209 | Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma |
| Q92424489 | Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program |
| Q37045880 | Seroprevalence and Correlates of Hepatitis C Virus Infection in Secondary School Children in Enugu, Nigeria |
| Q28539749 | Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya |
| Q64359315 | Seroprevalence of hepatitis B and C virus infections among diabetic patients in Kisangani (North-eastern Democratic Republic of Congo) |
| Q34630032 | Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia |
| Q56924599 | Systematic overview of hepatitis C infection in the Middle East and North Africa |
| Q63684425 | The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study |
| Q42746527 | The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management |
Search more.